ABT vs SI
ABT: A diversified global health care leader focused on diagnostic, medical device, nutritional, and pharmaceutical solutions. SI: Shoulder Innovations develops orthopedic devices for shoulder and upper extremity conditions, showing explosive revenue growth but facing profitability challenges and dramatic stock depreciation.
Side-by-side fundamentals
| Metric | ABT | SI | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $104.49 | $20.96 | |
| Market cap as of 2026-07-30 | $182.0B | $435M | |
| P/E as of 2026-07-30 | 35.28 | n/a | |
| PEG as of 2026-07-30 | 2.66 | -0.07 | SI lower |
| Net margin as of 2026-07-30 | +11.7% | -17.1% | ABT higher |
| Gross margin as of 2026-07-30 | +56.8% | +77.0% | SI higher |
| Operating margin as of 2026-07-30 | +15.8% | -55.4% | ABT higher |
| ROE as of 2026-07-30 | +12.2% | -13.6% | ABT higher |
| ROA as of 2026-07-30 | +6.9% | -10.9% | ABT higher |
| Debt / equity as of 2026-07-30 | 0.65 | 0.11 | SI lower |
| Revenue growth (YoY) as of 2026-07-30 | +8.1% | +151.0% | SI higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | n/a | |
| Dividend yield as of 2026-07-30 | +2.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-07-30 | 0.54 | 14.97 | |
| 1-year return as of 2026-07-27 close | -17.4% | n/a |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.